HUTCHMED (HCM) - Holzer & Holzer

ATLANTA, GA – – (ACCESSWIRE – May 5, 2022) – – Holzer & Holzer, LLC is investigating whether HUTCHMED Limited (“HUTCHMED” or the “Company”) (NASDAQ: HCM) complied with federal securities laws. On May 2, 2022, HUTCHMED announced that the FDA issued a Complete Response Letter regarding its New Drug Application. According to HUTCHMED, the FDA determined that the Company’s current data package does not support approval in the U.S. and that a multi-regional clinical trial that includes subjects more representative of the U.S. patient population is required. Following this announcement, the Company’s stock price dropped. If you purchased HUTCHMED stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.

View Complaint

View Representation Agreement

Provide Your Information To Take Action

Name*
First Last
Email*
Phone*
Address*
Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country
Shares Purchased:*
Date Purchased Number of Shares Acquired Acquisition Price Per Share
Shares Sold:
Date Sold Number of Shares Sold Selling Price Per Share
By clicking on the button below, I intend to sign and execute this Agreement and retain Holzer & Holzer, LLC to proceed on my behalf.*
- I agree.
Signed pursuant to the Uniform Electronic Transactions act as adopted by the various states and territories of the United States.
Signature*
CAPTCHA

Date Purchased	Number of Shares Acquired	Acquisition Price Per Share